Major trial launches for aggressive lung cancer that has returned

NCT ID NCT07365241

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study compares an experimental drug called ABBV-706 against standard chemotherapy treatments for adults whose small cell lung cancer has returned or stopped responding to prior therapy. About 531 participants will be randomly assigned to receive either the new drug or one of three standard treatments to see which is more effective and safer. The main goals are to see if the new drug helps shrink tumors and helps people live longer compared to current options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.